These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

929 related items for PubMed ID: 30196031

  • 21. Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
    de Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Olofsson Bagge R, Reimer T, Sund M, Christiansen P, Rydén L, Filtenborg Tvedskov T, SENOMAC Trialists’ Group.
    Lancet Oncol; 2024 Sep; 25(9):1222-1230. PubMed ID: 39121881
    [Abstract] [Full Text] [Related]

  • 22. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
    de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Rydén L, Olofsson Bagge R, Sund M, Johansson H, Lundstedt D, SENOMAC Trialists’ Group.
    BMC Cancer; 2017 May 26; 17(1):379. PubMed ID: 28549453
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.
    Houvenaeghel G, Boher JM, Reyal F, Cohen M, Garbay JR, Classe JM, Rouzier R, Giard S, Faure C, Charitansky H, Tunon de Lara C, Daraï E, Hudry D, Azuar P, Gimbergues P, Villet R, Sfumato P, Lambaudie E.
    Eur J Cancer; 2016 Nov 26; 67():106-118. PubMed ID: 27640137
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Positive axillary sentinel lymph node: is axillary dissection always necessary?
    Galimberti V, Chifu C, Rodriguez Perez S, Veronesi P, Intra M, Botteri E, Mastropasqua M, Colleoni M, Luini A, Veronesi U.
    Breast; 2011 Oct 26; 20 Suppl 3():S96-8. PubMed ID: 22015302
    [Abstract] [Full Text] [Related]

  • 27. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
    Houvenaeghel G, Cohen M, Raro P, De Troyer J, de Lara CT, Gimbergues P, Gauthier T, Faure-Virelizier C, Vaini-Cowen V, Lantheaume S, Regis C, Darai E, Ceccato V, D'Halluin G, Del Piano F, Villet R, Jouve E, Beedassy B, Theret P, Gabelle P, Zinzindohoue C, Opinel P, Marsollier-Ferrer C, Dhainaut-Speyer C, Colombo PE, Lambaudie E, Tallet A, Boher JM, Others investigators (SERC trial group).
    BMC Cancer; 2018 Nov 21; 18(1):1153. PubMed ID: 30463611
    [Abstract] [Full Text] [Related]

  • 28. [A new perspective on axillary dissection in situations of metastatic sentinel node].
    Zedníková I, Ňaršanská A, Hes O, Metelková A, Fiala O, Svoboda T.
    Rozhl Chir; 2017 Nov 21; 96(8):346-352. PubMed ID: 29058925
    [Abstract] [Full Text] [Related]

  • 29. Surgical management of early stage invasive breast cancer: a practice guideline.
    McCready D, Holloway C, Shelley W, Down N, Robinson P, Sinclair S, Mirsky D, Breast Cancer Disease Site Group of Cancer Care, Ontario's Program in Evidence-Based Care.
    Can J Surg; 2005 Jun 21; 48(3):185-94. PubMed ID: 16013621
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Omission of sentinel lymph node biopsy in patients with clinically axillary lymph node-negative early breast cancer (OMSLNB): protocol for a prospective, non-inferiority, single-arm, phase II clinical trial in China.
    Li X, Wang L, Wang Y, Ma L, Zheng R, Ding J, Gong Y, Yao H, Wang J, Zha X.
    BMJ Open; 2024 Sep 10; 14(9):e087700. PubMed ID: 39260835
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
    de Boniface J, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, Olofsson Bagge R, Rydén L, Sund M, SENOMAC Trialists’ Group.
    Breast Cancer Res Treat; 2020 Feb 10; 180(1):167-176. PubMed ID: 31989379
    [Abstract] [Full Text] [Related]

  • 37. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.
    Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot JL, Dunst J, Miguelez CG, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fischedick AR, Fietkau R, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, Pötter R, Gall C, Uter W, Strnad V, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO).
    Lancet Oncol; 2017 Feb 10; 18(2):259-268. PubMed ID: 28094198
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. 99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis.
    Wang J, Fan T, He Y, Chen X, Fan Z, Xie Y, Wang T, Li J, Ouyang T.
    Breast Cancer Res Treat; 2018 Apr 10; 168(2):365-370. PubMed ID: 29209873
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.